Adaptive kinase signaling enables escape from small molecule inhibition in glioblastoma
4 affiliations
- 1Maastro, Maastricht Radiation Oncology Institute, Maastricht, Netherlands
- 2Department of Radiation Oncology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, Netherlands
- 3Department of Surgery, NUTRIM Institute for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands
- 4Department of Medical Oncology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, Netherlands
Abstract
Objective: Patients with glioblastoma (GB) have a median survival of 15 months, despite intensive treatment with surgical resection, radiotherapy, and chemotherapy. A major challenge in overcoming treatment resistance is intratumoral heterogeneity, characterized by molecular, phenotypic, and clinical diversity. Small-molecule inhibitors (SMIs) target specific oncogenic signaling pathways and have become successful therapies in several molecularly defined cancers. In GB, however, SMIs have thus far failed to substantially improve patient outcomes. Here, we used a primary patient-derived glioblastoma organoid (PGO) platform to investigate adaptive bypass signaling mechanisms that drive resistance to targeted therapy.
Methods: Six primary PGOs were treated with nine FDA-approved SMIs selected for their blood–brain barrier permeability and ability to target key GB driver genes. Drug sensitivity was assessed by cell viability measurements and IC₅₀ determination. To identify compensatory signaling mechanisms, kinase activity profiling was performed following monotherapy treatment.
Results: Although inhibition of downstream effector proteins reduced cell viability more effectively (IC₅₀: 70 nM–1 μM) than inhibition of upstream receptor tyrosine kinases (IC₅₀: 1–15 μM), residual proliferation persisted in all PGOs. Kinase profiling revealed compensatory pathway activation following monotherapy, enabling the identification of effective SMI combinations. The most prominent combination targeted glycogen synthase kinase-3 (GSK-3) and mitogen-activated protein kinase kinase (MEK) using CHIR99021 and trametinib, respectively.
Conclusion: These findings demonstrate that adaptive bypass signaling limits single-agent SMI efficacy in GB. PGO-based kinase profiling enables the identification of resistance mechanisms and rational combination therapies, supporting its application in personalized treatment development.
Related
- Reversing the Hypoxic Adaptive Response in Breast Cancer Cells through Small-Molecule Inhibition of Oncogenic MicroRNA-210
- Combined HDAC and ATM inhibition with radiation in preclinical glioblastoma models
- Pannexin 1 inhibition reduces tumorigenic properties of patient-derived glioblastoma cells through the HIPPO and Wnt signalling pathways
- Lipid Nanoparticle Delivery of CAR276 mRNA Enables Antigen-Specific Cytotoxicity in T Cells Against Glioblastoma Cells
- Small-molecule ACOD1 inhibition attenuates colitis and tumor growth through a shared myeloid mechanism, diverging from genetic deletion
BibTeX
@article{heumen2026adaptive,
title = {{Adaptive kinase signaling enables escape from small molecule inhibition in glioblastoma}},
author = {Mike van Heumen and Linde Hoosemans and Jolanda Piepers and Sander S. M. Rensen and Kim R. Kampen and Ann Hoeben and Marc A. Vooijs},
journal = {Cancer Biology \& Therapy},
year = {2026},
month = nov,
doi = {10.1080/15384047.2026.2757335},
url = {https://doi.org/10.1080/15384047.2026.2757335},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Adaptive kinase signaling enables escape from small molecule inhibition in glioblastoma
AU - Mike van Heumen
AU - Linde Hoosemans
AU - Jolanda Piepers
AU - Sander S. M. Rensen
AU - Kim R. Kampen
AU - Ann Hoeben
AU - Marc A. Vooijs
PY - 2026
DA - 2026/11/03
JO - Cancer Biology & Therapy
DO - 10.1080/15384047.2026.2757335
UR - https://doi.org/10.1080/15384047.2026.2757335
AB - Objective: Patients with glioblastoma (GB) have a median survival of 15 months, despite intensive treatment with surgical resection, radiotherapy, and chemotherapy. A major challenge in overcoming treatment resistance is intratumoral heterogeneity, characterized by molecular, phenotypic, and clinical diversity. Small-molecule inhibitors (SMIs) target specific oncogenic signaling pathways and have become successful therapies in several molecularly defined cancers. In GB, however, SMIs have thus far failed to substantially improve patient outcomes. Here, we used a primary patient-derived glioblastoma organoid (PGO) platform to investigate adaptive bypass signaling mechanisms that drive resistance to targeted therapy. Methods: Six primary PGOs were treated with nine FDA-approved SMIs selected for their blood–brain barrier permeability and ability to target key GB driver genes. Drug sensitivity was assessed by cell viability measurements and IC₅₀ determination. To identify compensatory signaling mechanisms, kinase activity profiling was performed following monotherapy treatment. Results: Although inhibition of downstream effector proteins reduced cell viability more effectively (IC₅₀: 70 nM–1 μM) than inhibition of upstream receptor tyrosine kinases (IC₅₀: 1–15 μM), residual proliferation persisted in all PGOs. Kinase profiling revealed compensatory pathway activation following monotherapy, enabling the identification of effective SMI combinations. The most prominent combination targeted glycogen synthase kinase-3 (GSK-3) and mitogen-activated protein kinase kinase (MEK) using CHIR99021 and trametinib, respectively. Conclusion: These findings demonstrate that adaptive bypass signaling limits single-agent SMI efficacy in GB. PGO-based kinase profiling enables the identification of resistance mechanisms and rational combination therapies, supporting its application in personalized treatment development.
SN - 1538-4047
SN - 1555-8576
ER -